Superficial siderosis

Superficial siderosis (also known as superficial siderosis of the central nervous system, or SS-CNS) is a rare neurological condition caused by chronic, repeated, or continuous low-grade bleeding (hemorrhage) into the subarachnoid space, the fluid-filled area surrounding the brain and spinal cord. Over time, iron from the breakdown of hemoglobin in blood deposits as hemosiderin on the surface of the brain, brainstem, spinal cord, and cranial nerves. This iron accumulation is toxic to neural tissue and leads to progressive neurological damage. The condition primarily affects the central nervous system, with particular vulnerability of the vestibulocochlear nerve (cranial nerve VIII), the cerebellum, and the spinal cord. The hallmark clinical triad of superficial siderosis consists of sensorineural hearing loss (often bilateral and progressive), cerebellar ataxia (difficulty with balance and coordination), and myelopathy (spinal cord dysfunction causing weakness and spasticity). Hearing loss is typically the earliest and most common symptom, occurring in over 90% of patients. Other features may include dementia or cognitive decline, anosmia (loss of smell), bladder dysfunction, and other cranial nerve deficits. Symptoms are progressive and can lead to significant disability over years to decades. The condition most commonly presents in adulthood, typically between the ages of 40 and 70. The underlying source of bleeding can include dural defects, tumors (particularly ependymomas or other posterior fossa tumors), vascular malformations, prior surgery, or trauma, though in a significant proportion of cases the bleeding source remains unidentified despite thorough investigation. Diagnosis is established through MRI of the brain and spinal cord, which characteristically shows a rim of low signal intensity (dark line) on T2-weighted and gradient echo sequences along the surfaces of the brain and spinal cord. Treatment focuses on identifying and surgically correcting the source of bleeding when possible, which is the most important step to halt disease progression. There is no established pharmacological treatment to reverse existing damage. Iron chelation therapy has been explored but remains investigational with limited evidence of benefit. Cochlear implants may be considered for severe hearing loss, though outcomes can be variable. Supportive care including physical therapy, occupational therapy, and management of spasticity is important for maintaining quality of life.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Superficial siderosis